Enhancing the value of regenerative medicine products and developing an environment for their implementation in society
First written in FY2024-Q1. 1 of 2 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RestatedAnnual report
「In May 2023, the company's initiative was selected under the Ministry of Economy, Trade and Industry's FY2022 second supplementary budget subsidy program, “Subsidy for Creating an Environment for the Social Implementation of Regenerative, Cellular and Gene Therapies,” and the company is developing an environment to expand the market for its already approved products and promote the clinical use of new products.」
The company continues to pursue selection for and the creation of an environment through subsidy programs to promote market expansion for already approved products and the clinical use of new products. - FY2024-Q1First statedAnnual report
「In May 2023, the company's initiative was selected under the Ministry of Economy, Trade and Industry's FY2022 second supplementary budget subsidy program, “Subsidy for Creating an Environment for the Social Implementation of Regenerative, Cellular and Gene Therapies,” and the company is developing an environment to expand the market for its already approved products and promote the clinical use of new products.」
The company disclosed for the first time that its initiative had been selected for a Ministry of Economy, Trade and Industry subsidy program for social implementation, in order to promote market expansion for already approved products and the clinical use of new products.